Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  GlaxoSmithKline Pharmaceuticals Limited    GLAXO   INE159A01016

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote National Stock Exchange O…
03/17/2017 03/20/2017 03/21/2017 03/22/2017 03/23/2017 Date
2740(c) 2750.05(c) 2740(c) 2747.5(c) 2760(c) Last
14 365 13 965 10 362 5 166 7 941 Volume
-1.44% +0.37% -0.37% +0.27% +0.45% Change
More quotes
Financials ( INR)
Sales 2017 29 200 M
EBIT 2017 4 157 M
Net income 2017 3 283 M
Finance 2017 8 976 M
Yield 2017 1,93%
Sales 2018 33 081 M
EBIT 2018 6 088 M
Net income 2018 4 590 M
Finance 2018 5 439 M
Yield 2018 2,07%
P/E ratio 2017 71,56
P/E ratio 2018 50,82
EV / Sales2017 7,67x
EV / Sales2018 6,88x
Capitalization 232 954 M
More Financials
Company
GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals.The company's product portfolio includes prescription medicines and vaccines.Its prescription medicines range across therapeutic areas such as anti-infective, dermatology,... 
Sector
Pharmaceuticals
Calendar
05/31Earnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline Pharmaceut
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE PHARMACEUT
03/15 GLAXOSMITHKLINE : Submits US Application To Expand Fluarix Indication
03/06 GLAXOSMITHKLINE : Reports Positive Phase IIIb Study Data For Nucala
02/23 GLAXOSMITHKLINE : Glaxo Gets Positive Headline Results On Relvar-Ellipta Asthma ..
02/17 GLAXOSMITHKLINE PHARMACEUTICALS : AKD Securities Limited Equity Research - Trigg..
02/16 Vectura Hits GBP9 Million Royalty Cap Under Skyepharma Legacy Deal
02/14 GLAXOSMITHKLINE PHARMACEUTICALS : GSK declares quarterly figures
02/14 GLAXOSMITHKLINE : ViiV Gets Encouraging HIV Treatment Trial Results
02/13 GLAXOSMITHKLINE PHARMACEUTICALS : Pharma Q3 profit dips 33 per cent at Rs 53 cro..
02/13 GLAXOSMITHKLINE PHARMACEUTICALS : Q3 Net Sales declines by 6% with an underlying..
02/09 GLAXOSMITHKLINE PHARMACEUTICALS : Glaxo booster
More news
Sector news : Pharmaceuticals - NEC
03:14a YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
03/23 TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
More sector news : Pharmaceuticals - NEC
Latest Tweets
2016#Indian #stocks: #Market: Glaxosmithkline Pharmaceuticals : Apr 2016 growth p.. 
2015#Indian #stocks: #Merger #Acquisition: Glaxosmithkline Pharmaceuticals : spar.. 
2015#Indian #stocks: #Market: Glaxosmithkline Pharmaceuticals : Sep 2015 growth p.. 
2015#IndiaBombay #stocks: #Merger #Acquisition: Glaxosmithkline Pharmaceuticals :.. 
2015#Indian #stocks: Glaxosmithkline Pharmaceuticals : #Market Analysts say: good.. 
More tweets
Qtime:6
Advertisement
Chart GLAXOSMITHKLINE PHARMACEUT
Duration : Period :
GlaxoSmithKline Pharmaceut Technical Analysis Chart | GLAXO | INE159A01016 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE P...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 2 753  INR
Spread / Average Target 0,10%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Deepak Shantilal Parekh Non-Executive Chairman
Andrew Aristidou Chief Financial Officer & Executive Director
Raju Krishnaswamy Executive Director & Technical Director
Vrishali Desai Vice President-Medical & Clinical Research
D. Sundaram Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PHARMA..0.64%3 561
JOHNSON & JOHNSON9.28%342 277
ROCHE HOLDING LTD.7.52%217 164
PFIZER INC.5.57%205 273
NOVARTIS AG-0.94%194 072
MERCK & CO., INC.7.49%174 344
More Results